1198408-35-3

Basic information

• Product Name: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate;tert-Butyl 4-(6-aminopyridin-3-yl)
• CAS NO: 1198408-35-3
• Molecular Formula: C₁₅H₂₃N₃O₂
• Molecular Weight: 277.36202
• Mol File: 1198408-35-3.mol

Chemical Properties

• Boiling Point: 422.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.134±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.80±0.26(Predicted)
• CAS DataBase Reference: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate(1198408-35-3)
• EPA Substance Registry System: tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate(1198408-35-3)

Safety Data

• Hazardous Substances Data: 1198408-35-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of bioactive molecules, making it a valuable asset in drug discovery and development.
Used in Organic Chemistry Research:
tert-butyl 4-(6-aMinopyridin-3-yl)piperidine-1-carboxylate is employed as a building block in synthetic organic chemistry, particularly for the creation of complex molecules with potential applications in various fields. Its versatility in forming different chemical structures makes it an essential tool for researchers in the field of organic chemistry.
Used in Lab Research:
Tert-butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate is used as a research chemical, providing insights into the synthesis and properties of related compounds. Its role in lab research is crucial for understanding the potential applications and limitations of this class of molecules.

Upstream product

• 1279030-84-0 tert-butyl 6-amino-3’,6’-dihydro-[3,4’-bipyridine]-1'(2’H)-carboxylate 
• 1231930-22-5 tert-butyl 6-nitropyridine-3′,6′-dihydro-[3,4′-pyridine]-1′(2′H)-carboxylate 
• 1072-97-5 5-bromo-2-pyridylamine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 39856-50-3 5-bromo2-nitropyridine 
• 1048970-17-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 766-11-0 5-bromo-2-fluoropyridine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 741683-15-8 4-(6-fluoro-3-pyridyl)-4-hydroxy-N-tert-butoxycarbonylpiperidine 
• 741683-17-0 4-(6-fluoro-3-pyridyl)-N-tert-butoxycarbonylpiperidine 
• 182344-63-4 N-(5-bromo-pyridin-2-yl)-2,2-dimethyl-propionamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 41780-52-3 N’-(1-benzylpiperidin-4-ylidene)-4-methylbenzenesulfonohydrazide 

Downstream Products

• 1198408-37-5 C₂₄H₂₇ClN₄O₃ 
• 1360055-29-3 6-tert-Butyl-8-fluoro-2-{2-hydroxymethyl-3-[5-(1'-isopropyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-6-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-2H-phthalazin-1-one 
• 1360055-30-6 6-tert-Butyl-2-{3-[5-(1'-ethyl-1',2',3',4',5',6'-hexahydro-[3,4]bipyridinyl-6-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2-hydroxymethyl-phenyl}-8-fluoro-2H-phthalazin-1-one 
• 1360055-67-9 6-tert-Butyl-8-fluoro-2-{2-hydroxymethyl-3-[1-methyl-5-(1'-methyl-1',2',3',4',5',6'-hexahydro-[3,4]bipyridinyl-6-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-phenyl}-2H-phthalazin-1-one 
• 1360056-63-8 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(5-(5-(1-isopropylpiperidin-4-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)benzyl acetate 
• 1360056-65-0 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(5-(5-(1-ethylpiperidin-4-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)benzyl acetate 
• 1360057-17-5 2-(6-tert-butyl-8-fluoro-1-oxophthalazin-2(1H)-yl)-6-(1-methyl-5-(5-(1-methylpiperidin-4-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl)benzyl acetate 
• 1360057-06-2 C₄₁H₄₆FN₇O₆ 

Relevant articles and documents

INHIBITORS OF TRPC6

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Process method suitable for amplification preparation of 4-(6-aminopyridin-3-yl) substituted piperidine

The invention discloses a process method suitable for amplification preparation of 4-(6-aminopyridin-3-yl) substituted piperidine, and belongs to the synthesis field of a medicine intermediate. N-substituted piperidone, aryl sulfohydrazide and 2-amino-5-bromopyridine are subjected to a coupling reaction under a palladium catalyst, and then are subjected to a hydrogenation to obtain 4-(6-aminopyridin-3-yl) substituted piperidine. According to the process, the raw materials in pyridine do not need to be protected; the condensation and the coupling are carried out in the same reaction kettle, sothat the operation cost is reduced, the steps of performing protection at first and then performing protection removal as in documents can be avoided, and production cost of the existing biological, medicine and chemical intermediates is greatly reduced; and the process is subjected to amplification verification in kilogram-scale, and the verification proves that the yield and the product purity are basically equal to those of gram-scale, so that the method can be used as a process for industrial scale production.

SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.

PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Preparation method and intermediate of pyridinopyrimidine derivative

The invention relates to a preparation method and an intermediate of a pyridinopyrimidine derivative. Specifically, the invention provides a compound as shown in a formula I which is described in thespecification and a method for preparing the pyridinopyr

Streamlined Synthesis of Diaminopyridines by Pd-Catalyzed Ammonia Coupling with Deactivated Amino-Chloropyridines

An efficient and cost-effective two-step synthesis of diaminopyridines, fundamental building blocks of biologically active compounds, is reported. The advantages over previously reported routes include cost and wider availability of the bromo-chloropyridine starting materials and the straightforward accessibility to an extended array of diaminopyridine regioisomers. The key enabler of this synthetic strategy is the development of an unprecedented palladium-catalyzed coupling reaction of ammonia with chloropyridines deactivated by the presence of an alkylamino substituent. The coupling reaction was accomplished with very low catalyst loadings under remarkably mild reaction conditions, making the system particularly suitable for both academic and industrial applications. The utility of this methodology is exemplified by the application to the synthesis of highly relevant scaffolds, including the synthetic intermediates of the marketed drugs Ribociclib and Palbociclib.

SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG

Disclosed is a substituted 2H-pyrazole derivative serving as a selective CDK4/6 inhibitor. Specifically, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt thereof which serves as a selective CDK4/6 inhibitor.

PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF

The present invention discloses a pyrimidine or pyridopyridone compound as shown in formula (I) and an application thereof relating to the technical field of medicament preparation. The compound can selectively suppress cyclin-dependent kinases (Cdks) CDK

PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.